Co announced that researchers have completed preliminary preclinical studies showing that ranolazine increased glucose stimulated insulin secretion in pancreatic beta cells. In separate experiments ...
In January 2006, the U.S. Food and Drug Administration (FDA) approved a new antianginal agent for the treatment of chronic stable angina, ranolazine (Ranexa™; CV Therapeutics, Inc.). The drug, ...
Palo Alto, California Fears over QT prolongation are mounting for a range of already approved drugs, as well as for agents still in the pipeline. This past week, ranolazine, CV Therapeutics' new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results